S

Sage Therapeutics
D

SAGE

9.19000
USD
0.10
(1.04%)
مغلق
حجم التداول
175,175
الربح لكل سهم
-3
العائد الربحي
-
P/E
-2
حجم السوق
575,498,652
أصول ذات صلة
A
ACAD
-0.285
(-1.34%)
20.955 USD
ALNY
ALNY
-4.39
(-1.33%)
325.26 USD
C
CRSP
0.455
(0.88%)
52.120 USD
INCY
INCY
0.300
(0.44%)
68.470 USD
I
IONS
-0.450
(-1.03%)
43.190 USD
O
OPK
0.01500
(1.12%)
1.36000 USD
REGN
REGN
-0.69
(-0.13%)
546.88 USD
VRTX
VRTX
2.24
(0.49%)
459.27 USD
المزيد
الأخبار المقالات

العنوان: Sage Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.